FDA Approves Zyn Marketing as Less Harmful Than Cigarettes
The U.S. Food and Drug Administration has authorized Philip Morris to market 20 variants of its Zyn nicotine pouches with claims of reduced harm compared to cigarettes. This clearance, based on the assertion that Zyn use lowers the risk of various tobacco-related diseases, allows for marketing these products as beneficial to individual users and the public’s health. The decision comes as nicotine pouches represent the fastest-growing nicotine product in the U.S., experiencing significant sales increases for Philip Morris.
John Q. Hosedrinker